- Report
- November 2022
- 191 Pages
From €3047EUR$3,450USD£2,602GBP
- Report
- November 2022
- 193 Pages
North America
From €3047EUR$3,450USD£2,602GBP
- Report
- November 2022
- 197 Pages
Middle East, Africa
From €3047EUR$3,450USD£2,602GBP
- Report
- August 2022
- 330 Pages
Global
From €3930EUR$4,450USD£3,357GBP
- Report
- February 2022
- 211 Pages
Global
From €3930EUR$4,450USD£3,357GBP
- Report
- January 2022
- 163 Pages
Global
From €3930EUR$4,450USD£3,357GBP
- Report
- January 2022
- 181 Pages
Global
From €3930EUR$4,450USD£3,357GBP
- Report
- February 2024
- 118 Pages
Global
From €4195EUR$4,750USD£3,583GBP
- Report
- February 2024
- 115 Pages
Global
From €4195EUR$4,750USD£3,583GBP
- Report
- April 2023
- 110 Pages
Global
From €4195EUR$4,750USD£3,583GBP
- Report
- April 2023
- 100 Pages
Global
From €4195EUR$4,750USD£3,583GBP
- Report
- August 2022
- 135 Pages
Global
From €4195EUR$4,750USD£3,583GBP
- Report
- June 2022
- 138 Pages
Global
From €4195EUR$4,750USD£3,583GBP
- Report
- March 2022
- 112 Pages
Global
From €4195EUR$4,750USD£3,583GBP
- Report
- January 2022
- 117 Pages
Global
From €4195EUR$4,750USD£3,583GBP
- Report
- January 2022
- 120 Pages
Global
From €4195EUR$4,750USD£3,583GBP
- Clinical Trials
- April 2025
- 40 Pages
From €1104EUR$1,250USD£943GBP
- Report
- June 2024
- 200 Pages
Global
From €7021EUR$7,950USD£5,997GBP
- Report
- June 2024
- 180 Pages
Global
From €7021EUR$7,950USD£5,997GBP
- Report
- June 2024
- 206 Pages
Global
From €7021EUR$7,950USD£5,997GBP

The Monoclonal Antibodies market is a subset of the biotechnology industry that focuses on the production and use of monoclonal antibodies (mAbs). mAbs are laboratory-produced proteins that are designed to bind to specific targets, such as proteins, cells, or tissues. They are used in a variety of applications, including diagnostics, therapeutics, and research.
The market for mAbs is growing rapidly, driven by advances in biotechnology and the increasing demand for personalized medicine. mAbs are used in a variety of treatments, including cancer, autoimmune diseases, and infectious diseases. They are also used in research to develop new treatments and to improve existing treatments.
The market for mAbs is highly competitive, with many companies offering a wide range of products. Major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are investing heavily in research and development to develop new mAbs and to improve existing products.
In conclusion, the Monoclonal Antibodies market is an important part of the biotechnology industry, with many companies investing heavily in research and development to develop new products and improve existing treatments. Major players in the market include AbbVie, Amgen, AstraZeneca, Show Less Read more